SCHEMBL905307

SCHEMBL905307

O=[C]CC=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11461024 0.67
SCHEMBL7975382 0.64
SCHEMBL7933276 0.61
SCHEMBL44990 0.61
SCHEMBL9135233 0.61
SCHEMBL4529855 0.61
SCHEMBL343501 0.61
SCHEMBL7068378 0.61
SCHEMBL10785348 0.61
SCHEMBL28133972 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210023094-A1 PSMA ANTIBODY-DRUG CONJUGATES PSMA DEVELOPMENT COMPANY, LLC (US) 2021-01-28 US claimed
EP-2727606-A2 Compounds for killing psma-expressing, taxane-resistant cancer cells Psma Development Company, L.L.C. (US) 2014-05-07 EP claimed
EP-1912677-B1 PSMA antibody-drug conjugates PSMA DEV COMPANY L L C (US) 2013-10-02 EP claimed
EP-2326350-B1 COMPOUNDS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS PSMA DEV COMPANY L L C (US) 2013-09-04 EP claimed
EP-1718667-B1 HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES GENENTECH INC (US) 2013-01-09 EP claimed
EP-2326350-A2 METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS Psma Development Company, L.L.C. (US) 2011-06-01 EP claimed
US-7884053-B2 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation BOSTON PROBES, INC. (US) 2011-02-08 US claimed
US-7754681-B2 Heterocyclic self-immolative linkers and conjugates SEATTLE GENETICS, INC. (US) 2010-07-13 US claimed
WO-2010027513-A2 METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS PSMA DEVELOPMENT COMPANY, LLC (US) 2010-03-11 WO claimed
JP-4408628-B2 2010-02-03 JP claimed
US-20050256030-A1 for linking drug moieties to ligands; comprises a peptide sequence that is a substrate for an intracellular enzyme, for example a cathepsin, that cleaves the peptide at an amide bond SEAGEN INC. 2005-11-17 US claimed
WO-2005082023-A2 HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES GENENTECH, INC. (US) 2005-09-09 WO claimed
JP-2004524032-A 2004-08-12 JP claimed
EP-1412517-A4 METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS BOSTON PROBES INC (US) 2004-07-07 EP claimed
EP-1412517-A2 METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS Boston Probes, Inc. (US) 2004-04-28 EP claimed
US-20030077608-A1 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation APPLIED BIOSYSTEMS, LLC 2003-04-24 US claimed
WO-2002072865-A2 METHODS, KITS AND COMPOSITIONS OF COMBINATION OLIGOMERS BOSTON PROBES, INC. (US) 2002-09-19 WO claimed
EP-0624377-B1 Lysosomal enzyme-cleavable antitumor drug conjugates BRISTOL MYERS SQUIBB CO (US) 2002-01-23 EP claimed
US-6214345-B1 ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR BRISTOL-MYERS SQUIBB CO. 2001-04-10 US claimed
EP-0624377-A2 Lysosomal enzyme-cleavable antitumor drug conjugates Bristol-Myers Squibb Company (US) 1994-11-17 EP claimed